Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
about
Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling.Natural killer cells regulate murine cytomegalovirus-induced sialadenitis and salivary gland disease.Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland functionImpaired vascular responses to parasympathetic nerve stimulation and muscarinic receptor activation in the submandibular gland in nonobese diabetic mice.Unraveling the pathophysiology of Sjogren syndrome-associated dry eye diseaseNCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.Cholinergic Autoantibodies from Primary Sjögren's Syndrome Inhibit Mucin Production via Phospholipase C and Cyclooxygenase-2 In the Rat Submandibular Gland.Sjögren's syndrome: studying the disease in mice.Mechanisms involved in injury and repair of the murine lacrimal gland: role of programmed cell death and mesenchymal stem cellsSingle-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patientsSjögren syndrome: advances in the pathogenesis from animal models.Sexual dimorphism in an animal model of Sjögren's syndrome: a potential role for Th17 cells.Diverse mediators modulate the chloride ion fluxes that drive lacrimal fluid production.Usefulness of mouse models to study the pathogenesis of Sjögren's syndrome.Animal models in autoimmune diseases: lessons learned from mouse models for Sjögren's syndrome.Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjögren's syndrome.Muscarinic type 3 receptor autoantibodies are associated with anti-SSA/Ro autoantibodies in Sjögren's syndromeInducible nitric oxide synthase increases secretion from inflamed salivary glands.Classification criteria and treatment modalities in primary Sjögren's syndrome.Update on Pathogenesis of Sjögren's syndrome.An experimental protocol for the fractionation and 2DE separation of HeLa and A-253 cell lysates suitable for the identification of the individual antigenic proteome in Sjögren's syndrome.Acute salivary gland hypofunction in the duct ligation model in the absence of inflammation.Changes in Rab3D expression and distribution in the acini of Sjögren's syndrome patients are associated with loss of cell polarity and secretory dysfunction.Epithelial disruptions, but not immune cell invasion, induced secretory dysfunction following innate immune activation in a novel model of acute salivary gland injury.Capsaicin regulates the NF-κB pathway in salivary gland inflammation.Dental hygiene registration: development, and reliability and validity testing of an assessment scale designed for nurses in institutions.Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren's syndrome?Myoepithelial cell-driven acini contraction in response to oxytocin receptor stimulation is impaired in lacrimal glands of Sjögren's syndrome animal models.
P2860
Q30415532-D3E17BD9-9832-4514-86FF-AAF2460DF623Q30425772-75C6B37C-5532-454B-9A43-0DD44E8494D8Q30437519-0A908D66-4C4B-4700-BF38-82876D4C3B59Q33406637-DC1E657C-E12C-4048-8AE8-E25D2696F20BQ33819490-2EB9F219-153D-4374-84BA-8FEF6B3B197CQ34541173-D43F1D67-98A4-4379-B7F2-32DF6B0ED721Q35031736-2079236E-A0DD-4571-9324-D0780AFCB3B1Q35224700-6B5C7DB9-EA58-4410-8A0F-E81EF3893214Q35557789-18087198-9F69-4493-9C92-3CD349BA1E32Q35575645-691E69FB-7FBA-4D54-B7A4-0D10C5C79DCAQ36019008-38C64926-F0AF-4067-8EFB-3FAB25B21B32Q36226075-6A0828E8-A374-4774-8049-BC79E98AE408Q36506691-101BABA7-0EAB-40AE-B6ED-EEDB866328B5Q36801985-7E52B509-258B-42F3-81CA-2B2035D5E537Q36852657-AB030A05-78F7-4892-9100-81EFA4CA5EC8Q37016308-A5A8101B-A8DE-42F4-8D72-B1CD0D19FFF2Q37247050-F1662AC6-FB66-4B19-BF5D-A14E5EB9ED7FQ37284248-EE257DFC-4E2F-4F3D-B781-1E11201A4D75Q37462527-E44FB0B3-96DE-4527-B095-183FB1AF3791Q38197287-2A594835-2742-4F45-AECD-B0898DF338DEQ38559605-36A4BBB7-CEE9-4F20-B21A-E937361A59A5Q39482700-9084E9F6-1960-42BC-9985-FF9C84DDE923Q41434699-71CA976D-062F-480B-83BE-09D03C27078DQ42490500-B5A920A3-5C5F-499B-83DF-20617F30A7A2Q47379079-8F2004DD-EC05-4456-9F2F-358A3575DC04Q51057189-251F8C66-E3F2-4A76-B778-B8DAF856228AQ53081760-402DEBD0-5AE2-44C8-AD96-3BD046B9A343Q54530879-2D826B7B-8C1F-4CE8-A98E-E193086E536FQ55506109-4D63B178-3976-4C30-9C45-1CFCB5443B67
P2860
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@ast
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@en
type
label
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@ast
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@en
prefLabel
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@ast
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@en
P2093
P2860
P356
P1433
P1476
Sjogrens syndrome--the non-apoptotic model of glandular hypofunction.
@en
P2093
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEL067
P577
2006-04-04T00:00:00Z